Efficacy and duration of action of sustained-release diltiazem in patients with chronic stable effort angina

R. Lagioia, D. Scrutinio, A. Montesano, M. Clemente, F. Mastropasqua, F. Massari, L. Sorgente, P. Rizzon

Research output: Contribution to journalArticlepeer-review

Abstract

This double-blind, randomized, placebo-controlled, crossover study was designed to evaluate the effect and duration of sustained-release diltiazem (DTZ-SR) BID in 16 men with stable effort angina. Exercise tests were performed 8 and 12 hours after the administration of DTZ-SR or placebo. Blood samples for diltiazem plasma concentration levels were taken immediately prior to the exercise test at 12 hours. Statistical analysis was performed using an analysis of variance model for a crossover design. Compared with placebo, DTZ-SR significantly prolonged total work from 1982 ± 992 Kjoules/min to 2327 ± 876 Kjoules/min (+17.4%; P <0.01) at 8 hours and from 1744 ± 691 Kjoules/min to 2414 ± 987 Kjoules/min (+38.4%; P <0.01) at 12 hours after administration. Work load at ischemic threshold was also significantly prolonged from 1010 ± 384 Kjoules/min to 1249 ± 553 Kjoules/min (+ 23.6%; P <0.01) at 8 hours and from 963 ± 425 Kjoules/min to 1210 ± 639 Kjoules/min (+26%; P <0.01) at 12 hours. In conclusion, our data show that this sustained-release diltiazem BID formulation improves the exercise tolerance of patients with chronic angina and this therapeutic effect persists for up to 12 hours after administration.

Original languageEnglish
Pages (from-to)672-679
Number of pages8
JournalCurrent Therapeutic Research
Volume54
Issue number6
DOIs
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Efficacy and duration of action of sustained-release diltiazem in patients with chronic stable effort angina'. Together they form a unique fingerprint.

Cite this